CoChat

Saxagliptin improves glycaemic control and C‐peptide secretion in latent autoimmune diabetes in adults (LADA)

Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N., Hirshberg, B. · 2016 · Diabetes/Metabolism Research and Reviews
Cited by 62

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: To assess the efficacy and tolerability of saxagliptin and C‐peptide secretion in patients with diagnosed type 2 diabetes classified as glutamic acid decarboxylase antibody (GADA)‐positive or GADA‐negative. Methods: Post hoc analysis of data pooled from five randomized, placebo‐controlled, 24‐week phase 3 studies (n = 2709) was conducted. We evaluated mean change from baseline at week 24 in HbA 1c, fasting plasma glucose, postprandial plasma glucose, fasting and postprandial C‐peptide, and HOMA2‐%β and the proportion of patients achieving HbA 1c < 7% (53 mmol/mol) at week 24. Results: Saxagliptin produced greater adjusted mean reductions from baseline in HbA 1c versus placebo for GADA‐negative [difference vs placebo (95% CI), −0.62% (−0.71% to −0.54%); −6.8 mmol/mol (−7.8, −5.9)] and GADA‐positive patients [−0.64% (−1.01% to −0.27%); −7.0 mmol/mol (−11.0, −3.0)]. Consistently, saxagliptin produced a greater reduction from baseline in fasting plasma glucose and postprandial plasma glucose versus placebo in GADA‐positive versus GADA‐negative patients, and more patients achieved HbA 1c < 7% (53 mmol/mol) with saxagliptin versus placebo in both GADA‐negative and GADA‐positive patients. Saxagliptin increased β‐cell function as assessed by HOMA2‐%β and postprandial C‐peptide area under the curve from baseline in patients in both GADA‐positive and GADA‐negative patients. Adverse events and hypoglycaemic events were similar across treatment groups and GADA categories. Conclusion: Saxagliptin was effective in lowering blood glucose levels and generally well tolerated in GADA‐positive patients. Interestingly, saxagliptin appears to improve β‐cell function in these patients, although a longer treatment duration may be needed to confirm this finding. Copyright © 2015 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.2717

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 62

Metadata

Authors
Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N., & Hirshberg, B.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2015-10-28
Volume
32
Issue
3
Pages
289-296
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1917326214
Cited by
62
References
9
FWCI
4.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.